Dynavax Technologies | Betriebsaufwand



Operating Expenses Veränderung Datum
AbbVie USD 16.59B 5.96B 2024-12
Adma Biologics USD 80.47M 268K 2024-12
Amgen USD 6.78B 401M 2024-12
AstraZeneca USD 12.86B 2.06B 2024-12
Biogen USD 2.01B 13.3M 2024-12
BioMarin Pharmaceutical USD 585.91M 45.94M 2024-12
Bristol-Myers Squibb USD 11.55B 1.84B 2024-12
Dynavax Technologies USD 73.66M 3.12M 2024-12
Gilead Sciences USD 5.12B 1.54B 2024-12
Glaxosmithkline GBP 7.42B 408M 2024-12
Merck USD 11.33B 1.4B 2024-12
Neurocrine Biosciences USD 485.7M 47.4M 2024-12
Novartis USD 11.28B 1.73B 2024-12
Pfizer USD 18.17B 5.63B 2024-12
Regeneron Pharmaceuticals USD 2.8B 26.53B 2024-12
Roche Holding CHF 11.43B 1.48B 2024-12
Sarepta Therapeutics USD 496.73M 51.76M 2024-12
TG Therapeutics USD 78.24M 6.79M 2024-12
Vertex Pharmaceuticals USD 1.89B 230.4M 2024-12



Dynavax Technologies Betriebsaufwand - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Mar 2025.